Bio-Path Holdings Inc. (BPTH): Earnings growth forecast for next year

Bio-Path (BPTH) - corporate logo

The development of targeted therapy to block tumor proteins is driving growth for Bio-Path Holdings (BPTH). Shifts in analyst EPS growth estimates reflect current trends, where the 51.20 metric determines the parameter status. High pricing power potential in hematology via DNAbilize is coupled with capital dilution risks stemming from frequent secondary offerings and uncertainty regarding clinical trial timelines.

BPTH: Bio-Path Holdings Inc. Net earnings per share growth forecast for next year 07/04/2022 - 03/01/2025

Metric breakdowns and analytics for biopathholdings.com (BPTH)

- price and consensus price forecast:
Price Chart Bio-Path|BPTH - Average Forecast Price
- stock exchange capitalization data:
Market Capitalization Bio-Path Holdings|BPTH - Business Value
- book capitalization indicators:
Book Value per Share Bio-Path Holdings|BPTH - Company Book Value|Market Capitalization to Book Value Ratio biopathholdings.com|BPTH - Company Total Asset Base
- debt obligations and liquidity statistics:
Debt to Equity Bio-Path Holdings|BPTH - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Bio-Path Holdings, Inc.|BPTH - Company Total Indebtedness|Debt to Book Capitalization Ratio Bio-Path Holdings|BPTH - Long-Term Liabilities|Company Short-Term Debts Bio-Path Holdings|Quick Liquidity Indicator biopathholdings.com
- earnings and valuation multiples information:
BPTH - Profit After Payment of Taxes|Projected Future Earnings Bio-Path Holdings|BPTH - Company Value to Net Income|Projected Price to Earnings Bio-Path Holdings|BPTH - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Bio-Path Holdings|BPTH - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Bio-Path Holdings|BPTH - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months biopathholdings.com|BPTH - Earnings per share growth in current year|Earnings growth forecast for next year Bio-Path Holdings
Analysis of all company metrics:BPTH, Bio-Path
Core merchandise of Bio-Path Holdings Inc.

This indicator measures the percentage change in expected earnings per share (EPS) for the following year, aggregating analyst consensus forecasts to assess future profitability. For Bio-Path Holdings (BPTH), which lacks commercial products and relies on equity issuance, the expected EPS growth for next year reflects the market's speculative faith in the success of clinical trials amid the absence of its own cash flow.

Who Bio-Path Holdings competes with

Net earnings per share growth forecast for next year TG Therapeutics Corp|Expected net earnings per share growth next year Arcellx Therapeutics ACLX|Earnings growth forecast for next year IRON|syndax.com - Projected earnings per share growth rate for next year|Earnings growth forecast for next year KURA (Kura Oncology)|ADC Therapeutics S.A. - Net earnings per share growth forecast for next year|Foghorn - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Vor Bio Inc. VOR|nkartatx.com (NKTX) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Coeptis Therapeutics, Inc. (COEP)|Expected earnings per share growth for next year ATNM|ESLA - Net earnings per one share growth forecast for next year|Net earnings per share growth forecast for next year CASI Pharmaceuticals (CASI)|MRKR: Net earnings per share change forecast for next year|Earnings growth forecast for next year INAB (IN8bio, Inc.)|Earnings growth forecast for next year Eterna Therapeutics, Inc. ERNA|GTBP: Expected earnings per share growth for next year|Aptose Biosciences Inc. - Projected earnings per share increase next year|MEIP: Earnings growth forecast for next year|Vincerx Pharma - Expected earnings per share trend next year